Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been clinically diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel) and received a standard dose of a clot-busting medication called tenecteplase by IV drip within 4.5 hours of their stroke starting
• People whose stroke symptoms fall within a specific range of severity, measured using a standard stroke scale (called the NIHSS), both before and after receiving the clot-busting medication
• People for whom the study treatment (tirofiban or a placebo) can be started within 6 hours of receiving the clot-busting medication
• People who were largely independent in daily life before the stroke, based on a standard disability rating scale (confirm with trial site)
• People whose brain scan after receiving the clot-busting medication shows no bleeding in the brain

Who may not be able to join:

• People who have received, or are planned to receive, a combined clot-removal procedure alongside the clot-busting medication (confirm with trial site)
• People whose brain scan shows a very large area of stroke-affected brain tissue (covering more than one-third of a specific region of the brain)
• People who have an irregular heart rhythm called atrial fibrillation, or whose stroke is suspected to have been caused by a blood clot from the heart
• People who have had epileptic seizures alongside their stroke
• People who have taken blood-thinning, anti-clotting, or clot-dissolving medications in the 24 hours before joining the trial
• People who are actively bleeding or show signs of a tendency to bleed after receiving the clot-busting medication
• People who have had bleeding in the digestive system, urinary system, eyes, or elsewhere in the body within the past year
• People with severely reduced kidney or liver function, based on specific blood test results (confirm with trial site for exact values)
• People with a life expectancy of less than 3 months
• People who are pregnant or breastfeeding
• People with a known allergy to tirofiban (the study drug)
• People who are currently enrolled in, or have been enrolled in, another clinical trial within the past 3 months
• People who are unlikely to attend follow-up appointments or are expected to have difficulty following the study requirements
• People the research team considers unsuitable for the trial for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.